Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 12/20 | 0.45 |
| ▸ | F7 | P08709 | 10/20 | 0.45 |
| ▸ | F2 | P00734 | 10/20 | 0.44 |
| ▸ | F10 | P00742 | 9/20 | 0.44 |
| ▸ | PLG | P00747 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5885658 | 0.88 | F10 (0.39) | F3F2F10PLGEGLN1 | |
| SCHEMBL5885861 | 0.87 | PPARG (0.38) | F3F7F2F10PLG | |
| SCHEMBL5885753 | 0.87 | F10 (0.35) | F3F7F2F10PLG | |
| Hydrochloric Acid SCHEMBL5886017 | 0.86 | PPARG (0.38) | F3F7F2F10PLG | |
| SCHEMBL5885576 | 0.85 | PPARG (0.37) | F3F7F2F10PLG | |
| SCHEMBL5885670 | 0.85 | F10 (0.37) | F3F7F2F10PLG | |
| Hydrochloric Acid SCHEMBL5885879 | 0.84 | PPARG (0.37) | F3F7F2F10PLG | |
| SCHEMBL5885785 | 0.84 | KMT2A (0.39) | GAAKMT2AHSD17B10ACACBEGLN1 | |
| SCHEMBL5885661 | 0.82 | PLAU (0.36) | F2F10PLGEGLN1PPARG | |
| SCHEMBL5886148 | 0.82 | F10 (0.39) | F2F10PLGEGLN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | claimed |
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | F3 3/4885F7 22/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.